Pediatric-Adult ME/CFS Comparison Study

1 Background and Rationale

The striking disparity between pediatric and adult ME/CFS recovery rates represents one of the most important clues to understanding recovery mechanisms. While estimates vary by study and definition, pediatric recovery rates of 54–94% contrast sharply with adult rates of \(\leq\) 22% (Rowe et al. 2017). This difference persists even when controlling for disease duration, suggesting that age-related biological factors—not merely time since onset—determine recovery probability. Several explanations for this differential have been proposed: developmental plasticity allowing biological “resetting” in younger patients (see the Glial Maturation Window hypothesis, Speculation Glial Maturation Window and Pediatric Recovery), active immune development enabling clearance of pathological processes (Hypotheses Immune Memory Pruning in Development and EBV-Adolescence Autoimmune Window), higher metabolic reserves in children, or greater regenerative capacity across multiple organ systems. However, no study has systematically compared the biological profiles of pediatric and adult ME/CFS patients to identify specific mechanisms underlying differential recovery. This study would provide the first comprehensive cross-sectional comparison of biological features between pediatric and adult ME/CFS patients, generating hypotheses about which systems drive recovery and informing development of targeted interventions.

2 Hypotheses

3 Study Design

3.1 Design Overview

This is a cross-sectional observational study comparing biological profiles between pediatric/adolescent and adult ME/CFS patients. The study includes both a discovery phase (comprehensive profiling) and a validation phase (replication in independent cohort).

3.2 Participants

Inclusion Criteria All participants:

  • ME/CFS diagnosis meeting IOM 2015 criteria (or pediatric equivalent)

  • Disease duration 6 months to 5 years (to minimize confounding by duration)

  • Stable disease (no major change in severity over past 3 months)

  • Able to provide informed consent (parental consent for minors) Pediatric cohort (n=100):

  • Age 10–17 years at enrollment

  • Tanner stage documented Adult cohort (n=100):

  • Age 25–55 years at enrollment

  • Premenopausal women or age-matched men Exclusion Criteria

  • Alternative diagnosis explaining symptoms

  • Active infection at time of assessment

  • Immunosuppressive medication within past 3 months

  • Pregnancy or lactation

  • Unable to tolerate study procedures

  • Severe psychiatric comorbidity precluding participation Stratification Within each age group, participants will be stratified by:

  • Severity (mild, moderate, severe using Bell scale)

  • Trigger type (post-infectious vs. other)

  • Sex (target 70% female in each group, reflecting epidemiology)

3.3 Control Groups

  • Healthy controls: 50 pediatric, 50 adult, matched for age and sex
  • Disease controls: 25 pediatric, 25 adult with other post-viral fatigue syndromes (recovered from acute infection but with persistent fatigue not meeting ME/CFS criteria)

4 Measures

4.1 Epigenomic Assessment

  • Genome-wide DNA methylation via Illumina EPIC array
  • Epigenetic age calculation (Horvath, GrimAge, PhenoAge clocks)
  • Targeted methylation at immune-related genes
  • Histone modification assays (H3K4me3, H3K27ac) at selected loci

4.2 Immune Profiling

  • Extended flow cytometry panels:
    • T cell subsets: naive (CD45RA+CCR7+), central memory, effector memory, TEMRA, exhaustion markers (PD-1, CTLA-4, LAG-3)
    • B cell subsets: naive, memory, plasmablasts, CD21lo atypical memory
    • NK cell subsets: CD56bright vs. CD56dim, cytotoxicity markers
    • Monocyte subsets: classical, intermediate, non-classical
    • T regulatory cells: CD4+CD25hiFoxP3+
  • Recent thymic emigrants (CD31+ naive CD4 T cells)
  • NK cell cytotoxicity functional assay
  • T cell proliferation assay
  • Cytokine production capacity (intracellular staining after stimulation)
  • Autoantibody panel: GPCR autoantibodies, ANA, anti-neuronal antibodies
  • Inflammatory markers: high-sensitivity cytokine panel (30+ cytokines), CRP, ESR

4.3 Mitochondrial Function

  • PBMC respirometry (Seahorse XF assay): basal respiration, maximal capacity, spare respiratory capacity, ATP-linked respiration
  • Plasma acylcarnitine profile
  • Lactate:pyruvate ratio
  • CoQ10 levels
  • Muscle biopsy (optional subset, n=20 per group): electron microscopy, respiratory chain enzyme activities, mtDNA copy number

4.4 Metabolomic Profiling

  • Untargeted plasma metabolomics (LC-MS/MS)
  • Targeted panels: amino acids, organic acids, lipids
  • Metabolic flexibility assessment: RER dynamics during standardized mild challenge
  • Fasting insulin, glucose, HOMA-IR

4.5 Autonomic Assessment

  • 24-hour Holter monitoring with HRV analysis
  • NASA Lean Test (10-minute stand)
  • Baroreflex sensitivity
  • Pupillometry

4.6 Stem Cell and Regenerative Markers

  • TCR/BCR repertoire diversity via immunosequencing
  • Circulating progenitor cells (CD34+)
  • Telomere length (flow-FISH)
  • Senescence markers: p16INK4a expression, senescence-associated secretory phenotype (SASP) markers

4.7 Clinical Assessment

  • DSQ-PEM (DePaul Symptom Questionnaire)
  • Bell Disability Scale
  • MFI (Multidimensional Fatigue Inventory)
  • SF-36
  • Pediatric Quality of Life Inventory (PedsQL) for pediatric cohort
  • Detailed medical history and physical examination
  • 7-day actigraphy

5 Outcomes

5.1 Primary Outcomes

  • Composite Recovery Potential Index (RPI) score (see Section Recovery Potential Index Development)
  • Individual RPI component scores
  • Between-group differences in each biological domain

5.2 Secondary Outcomes

  • Correlations between biological markers and clinical severity
  • Identification of biological features unique to pediatric ME/CFS
  • Identification of biological features associated with shorter disease duration
  • Exploratory subtype identification via unsupervised clustering

6 Analysis Plan

6.1 Primary Analysis

Between-group comparisons (pediatric vs. adult) using:

  • ANCOVA adjusting for disease duration, severity, and sex
  • Effect sizes (Cohen’s d) and confidence intervals
  • False discovery rate correction for multiple comparisons

6.2 Secondary Analyses

  • Mediation analysis: Does any biological factor mediate the age-recovery relationship?
  • Network analysis: How do biological systems interact differently in pediatric vs. adult patients?
  • Machine learning: Can biological profiles classify patients by age group? What features drive classification?
  • Correlation with clinical measures: Which biological features predict symptom severity?

6.3 Power Analysis and Sample Size Justification

With n=100 per group:

  • 80% power to detect Cohen’s d=0.40 (medium effect) at \(\alpha\)=0.05 for continuous outcomes
  • 80% power to detect 15% difference in proportions
  • Sufficient for exploratory subgroup analyses (n=25+ per subgroup) Based on the dramatic difference in recovery rates (54–94% vs. \(\leq\) 22%), we anticipate large effect sizes (\(d>0.8\)) for biologically relevant differences, making n=100 per group well-powered.

7 Ethical Considerations

7.1 Pediatric-Specific Protections

  • Parental consent plus child assent required
  • Procedures minimized to reduce burden on ill children
  • Home visits offered for severely affected participants
  • Child life specialist available during procedures
  • Mandatory rest periods during assessment days
  • Parents may remain present for all procedures

7.2 General Protections

  • IRB approval at all participating sites
  • DSMB oversight
  • Procedures adapted to patient capacity (no procedures that would cause PEM)
  • Results returned to participants who request them (with genetic counseling as appropriate)
  • Samples stored in biorepository with consent for future research

8 Expected Outcomes and Implications

If the hypothesis is supported, this study would:

  • Identify specific biological systems that differ between pediatric and adult ME/CFS patients
  • Generate therapeutic targets for interventions aimed at “restoring” adult systems to more youthful states
  • Validate the Recovery Potential Index as a prognostic tool
  • Inform design of the Aggressive Early Intervention Trial (Section Aggressive Early Intervention Trial) If the hypothesis is not supported (no systematic biological differences), this would suggest that the recovery differential stems from psychosocial factors, disease recognition/treatment timing, or other non-biological mechanisms—itself an important finding that would redirect research priorities

References

Rowe, Peter C., Rosemary A. Underhill, Kenneth J. Friedman, Alan Gurwitt, Marvin S. Medow, Michael S. Schwartz, Nigel Speight, Julian M. Stewart, Rosamund Vallings, and Katherine S. Rowe. 2017. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer.” Frontiers in Pediatrics 5: 121. https://doi.org/10.3389/fped.2017.00121.